The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

The global race for weight loss solutions has firmly arrived in India—bringing with it hope, hype, and a host of unanswered ...

As weight-loss injectables like Ozempic skyrocket in popularity, a new offshoot trend is starting to take hold: microdosing. But experts have concerns.

Hims & Hers Health reports strong Q1 results with 111% revenue growth, 38% subscriber growth, and sets 2030 targets. Read ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that ...